⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765471 | 1.00 | — | — | |
| SCHEMBL1765469 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2232227 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2239793 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2232225 | 0.97 | — | — | |
| SCHEMBL23792888 | 0.82 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL1555156 | 0.80 | — | — | |
| SCHEMBL7741435 | 0.80 | — | — | |
| SCHEMBL1556637 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL1094574 | 0.78 | GABRR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025075817-A1 | METHODS FOR SYNTHESIS OF PROTEIN HETERO-POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-10 | — | — | WO | disclosed |
| US-11078202-B2 | β-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-11078202-B2 | β-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| CN-111670187-B | Beta-lactamase inhibitor and use thereof | 苏州信诺维医药科技有限公司 | 2021-04-16 | — | — | CN | disclosed |
| US-20210046057-A1 | Beta-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20210046057-A1 | Beta-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20210032260-A1 | Beta-lactamase inhibitor and use thereof | Evopoint Biosciences Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
| US-20210032260-A1 | Beta-lactamase inhibitor and use thereof | Evopoint Biosciences Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3744722-A1 | ß-LACTAMASE INHIBITOR AND USE THEREOF | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-20070249688-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| US-6846820-B2 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-6649634-B2 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | disclosed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |